Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Richard Lockey, University of South Florida
ClinicalTrials.gov Identifier:
NCT00584662
First received: December 21, 2007
Last updated: June 27, 2012
Last verified: July 2008

December 21, 2007
June 27, 2012
January 2005
March 2010   (final data collection date for primary outcome measure)
to evaluate the effectiveness through symptom scores of the addition of oxymetazoline to nasal GCS in subjects with resistant congestion despite . [ Time Frame: 9 WEEKS ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00584662 on ClinicalTrials.gov Archive Site
To evaluate the need for rescue medicine for persistent or worsening congestion.To evaluate evidence of rebound congestion in subjects treated with both nasal GCS and oxymetazoline.To evaluate improvement in the total nasal [ Time Frame: 9 WEEKS ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

Nasal glucocorticosteroids (GCS) are considered first-line therapy for both allergic and non-allergic rhinitis.1-3 Nasal congestion can persist despite maximum treatment with intranasal GCS. No other drugs are superior to intranasal GCS in relieving nasal congestion. For example, antihistamines are not effective in relieving congestion.1 Oral decongestants are somewhat beneficial in relieving nasal congestion but can elevate blood pressure, cause restlessness, and cause urinary retention. Oxymetazoline, however, is a potent decongestant and the addition of it to a nasal GCS should add a considerable decongestant benefit. It may also be beneficial in patients with persistent nighttime congestion despite maximum dosages of nasal GCS.

Oxymetazoline is currently recommended for three days use because of the proposed risk of rhinitis medicamentosa,4 which is increased nasal congestion caused by prolonged use of nasal decongestant sprays.5-8 The term RM was coined early in the twentieth century after several case reports described patients developing rebound congestion after using first generation intranasal decongestants such as privine hydrochloride and ephedrine for prolonged periods6,7. The histopathology and mechanism of RM has been based on animal models which may not be pertinent to humans.9-13 Studies using oxymetazoline, a newer intranasal decongestant, in individuals without rhinitis have shown conflicting evidence for the development of RM.14-16 For example, normal individuals without rhinitis using oxymetazoline three times daily for four weeks did not develop RM.17 Also, it is unknown the frequency of administration and dosage of oxymetazoline it takes to induce RM or whether RM is just a return to a patient's baseline nasal congestion as present before beginning oxymetazoline. It is also unknown whether RM is more likely or only occurs with older vasoconstrictors such as privine hydrochloride and ephedrine rather than oxymetazoline.

Nasal GCS reduce the amount of rebound congestion in patients with perennial allergic rhinitis who have reportedly developed RM.18 Nasal GCS decrease nasal mucosa edema, recruitment of neutrophils and mononuclear cells, cytokine production, and late-phase nasal mediators.19-21 They may offer a protective benefit from the risk of developing RM. Oxymetazoline may also decrease inferior turbinate hypertrophy thereby permitting better adsorption of the nasal GCS.

Hypothesis

The addition of oxymetazoline to a nasal GCS for fourteen days will decrease the amount of congestion in subjects with allergic or non-allergic rhinitis with persistent congestion despite maximum recommended dosages of a nasal GCS. It is also hypothesized that nasal GCS protect against the development of RM secondary to oxymetazoline.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Rhinitis
Drug: Oxymetazoline Hydrochloride
Oxymetazoline Hydrochloride TWO SPRAYS BID
Other Name: AFRIN
Active Comparator: 1
Oxymetazoline Hydrochloride
Intervention: Drug: Oxymetazoline Hydrochloride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
42
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male and female subjects 18 years of age and older
  2. At least a one year history of perennial allergic or non-allergic rhinitis
  3. Subjects receiving allergen immunotherapy must be on a stable maintenance regimen for at least 30 days before the first study visit and remain on this dosage during the study.
  4. Subjects must be on the maximum doses of one of the following nasal GCS for at least one month: beclomethasone, flunisolide, fluticasone, mometasone, or triamcinolone.
  5. Nasal Congestion Score of 2 or greater at screening visit (Day -7)
  6. Average Nasal Congestion Score of 1.5 or greater at baseline visit (Day 1). Average Nasal Congestion Score is calculated from over the last three days prior to baseline and the morning of the baseline visit (i.e. total of seven scores)
  7. Willingness to participate as indicated by signed informed consent

Exclusion Criteria:

  1. Presence of hypersensitivity to oxymetazoline or mometasone
  2. Women who are pregnant or lactating
  3. Women of childbearing potential who are not abstinent or not practicing a medically acceptable form of contraception
  4. Other nasal diseases likely to affect deposition of oxymetazoline such as sinusitis, nasal polyps, or nasal structural malformations
  5. No respiratory tract infections in the last 14 days
  6. Infections requiring antibiotics in the last 14 days
  7. No oxymetazoline or other nasal sprays in the last 14 days
  8. No cardiovascular disease, uncontrolled hypertension or hypertension requiring more than two drugs to achieve control, or arrythmias
  9. Subjects can not be on beta or alpha blockers
  10. No diabetes mellitus
  11. No presence or history of ocular herpes simplex, cataracts, or glaucoma
  12. Subjects who are currently alcohol or drug abusers
  13. Inability to cooperate, comply with study procedures or communicate with the investigator as needed to successfully complete the study
  14. No benign prostate hypertrophy
  15. A history of psychosis
  16. Patients with a planned hospitalization during the study
  17. History of drug or alcohol abuse within the past five years
  18. An infirmity, disability, or geographical location which seems likely to prevent regular attendance for patient visits
  19. No use of the following medicines or therapies within the time period specified below prior to Day -7:
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00584662
AFRIN STUDY
No
Richard Lockey, University of South Florida
University of South Florida
Not Provided
Principal Investigator: RICHARD F LOCKEY, MD USF
University of South Florida
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP